<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>349</serviceExecutionTime><Drug id="18156"><DrugName>helper virus-free HSV-1 amplicon (glioma), Harvard</DrugName><DrugSynonyms><Name><Value>helper virus-free HSV-1 amplicon (glioma), Harvard</Value></Name></DrugSynonyms><CompanyOriginator id="24839">Harvard Medical School</CompanyOriginator><CompaniesSecondary><Company id="24839">Harvard Medical School</Company></CompaniesSecondary><CrossReferences><SourceEntity id="24839" type="Company"><TargetEntity id="4296615285" type="organizationId">Harvard Medical School</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="1108">Glioma</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="4784">Herpes virus based gene therapy</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2009-12-23T07:38:59.000Z</LastModificationDate><ChangeDateLast>2009-12-23T07:38:59.000Z</ChangeDateLast><AddedDate>1998-07-07T16:43:34.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="24839"&gt;Harvard Medical School&lt;/ulink&gt; was investigating a helper virus-free HSV-1 amplicon which offers potential in the therapy of human glioma. The project was in the preclinical stage of development by 1998; it was believed that use of such a helper virus-free vector would reduce the risk to efficacy ratio for glioma gene therapy [&lt;ulink linkType="reference" linkID="290299"&gt;290299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The HSV-1 amplicon elicited dose-dependent ganciclovir sensitivity, in an MOI-dependent way, in rat 9L gliosarcoma and human T98 glioma cells. The sensitivity was maintained in transfected cells for five to seven generations (approximately 14 days) post infection [&lt;ulink linkType="reference" linkID="290299"&gt;290299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a study published in 2000, helper virus-free HSV-1 amplicon vectors appeared to be effective for cytokine-enhanced vaccination therapy of glioma, with the advantages that both dividing and nondividing tumor cells could be infected, no viral proteins were expressed, and these vectors were safe and compatible with clinical use [&lt;ulink linkType="reference" linkID="439242"&gt;439242&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24839">Harvard Medical School</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24839">Harvard Medical School</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-07-07T00:00:00.000Z</StatusDate><Source id="290299" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="34981"><DrugName>MX-6043</DrugName><DrugSynonyms><Name><Value>MX-6043</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PPARgamma antagonist, Maxia</Value></Name></DrugSynonyms><CompanyOriginator id="24819">Maxia Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="24819">Maxia Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="34981" type="Drug"><TargetEntity id="305205" type="siDrug">MX-6043</TargetEntity></SourceEntity><SourceEntity id="24819" type="Company"><TargetEntity id="4297851184" type="organizationId">Maxia Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4058" type="Action"><TargetEntity id="1674" type="Mechanism">Drugs Acting on RXR Receptors</TargetEntity><TargetEntity id="1893" type="Mechanism">Retinoid RXR Modulators</TargetEntity></SourceEntity><SourceEntity id="2481" type="Action"><TargetEntity id="892" type="Mechanism">PPARgamma Antagonists</TargetEntity></SourceEntity><SourceEntity id="1919" type="Action"><TargetEntity id="605" type="Mechanism">Insulin Sensitizers</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="PTGT-01596" type="ciTarget"><TargetEntity id="125063490854683" type="siTarget">Peroxisome proliferator-activated receptor gamma</TargetEntity><TargetEntity id="611" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="4058">Retinoid X receptor modulator</Action><Action id="1919">Insulin sensitizer</Action><Action id="2481">PPAR gamma antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="38208">Glitazone antidiabetic product</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A10B4</Code><Name>Glitazone antidiabetics</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T06:38:33.000Z</LastModificationDate><ChangeDateLast>2007-12-17T11:37:15.000Z</ChangeDateLast><AddedDate>2001-07-04T10:52:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="34981" linkType="Drug"&gt;MX-6043&lt;/ulink&gt; was a PPARgamma inhibitor under investigation by Maxia Pharmaceuticals for the potential treatment of type 2 diabetes [&lt;ulink linkID="414447" linkType="reference"&gt;414447&lt;/ulink&gt;]. However, in February 2003, Maxia was acquired by Incyte [&lt;ulink linkID="479261" linkType="reference"&gt;479261&lt;/ulink&gt;], and by May 2004, Maxia had been shut down and investigations into &lt;ulink linkID="34981" linkType="Drug"&gt;MX-6043&lt;/ulink&gt; had been discontinued [&lt;ulink linkID="536965" linkType="reference"&gt;536965&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2001, data were presented on &lt;ulink linkID="34981" linkType="Drug"&gt;MX-6043&lt;/ulink&gt; at the 61st ADA Scientific Sessions in Philadelphia, PA. In KKAy mice, maintained on a high-fat diet, &lt;ulink linkID="34981" linkType="Drug"&gt;MX-6043&lt;/ulink&gt; reduced glucose and triglyceride levels, increased serum leptin levels and reduced dietary consumption and weight gain compared to controls. In rats, fed a high-cholesterol atherogenic diet, &lt;ulink linkID="34981" linkType="Drug"&gt;MX-6043&lt;/ulink&gt; decreased total cholesterol, increased HDL cholesterol and lowered LDL cholesterol, thus reversing severe dyslipidemia. In vitro analysis suggested that &lt;ulink linkID="34981" linkType="Drug"&gt;MX-6043&lt;/ulink&gt; acted through RXR receptors, rather than PPAR receptors. These data suggested &lt;ulink linkID="34981" linkType="Drug"&gt;MX-6043&lt;/ulink&gt; may be particularly effective against cardiovascular complications of diabetes, such as atherogenesis [&lt;ulink linkID="414447" linkType="reference"&gt;414447&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24819">Maxia Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-05-06T00:00:00.000Z</StatusDate><Source id="536965" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24819">Maxia Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-07-04T10:52:31.000Z</StatusDate><Source id="414447" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01028"><Name>Insulin receptor</Name><SwissprotNumbers><Swissprot>P06213</Swissprot><Swissprot>P09208</Swissprot><Swissprot>P15127</Swissprot><Swissprot>P15208</Swissprot><Swissprot>Q28516</Swissprot><Swissprot>Q93105</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01596"><Name>PPAR gamma</Name><SwissprotNumbers><Swissprot>O18924</Swissprot><Swissprot>O18971</Swissprot><Swissprot>O19052</Swissprot><Swissprot>O62807</Swissprot><Swissprot>O88275</Swissprot><Swissprot>P37231</Swissprot><Swissprot>P37234</Swissprot><Swissprot>P37238</Swissprot><Swissprot>P57797</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01676"><Name>Retinoid X receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1604866" number="WO-02072543" title="RXR activating molecules"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Incyte Corp" id="17216"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="79202"><DrugName>Pseudomonas aeruginosa vaccines, Brigham and Women's Hospital</DrugName><DrugSynonyms><Name><Value>Pseudomonas aeruginosa vaccines, Brigham and Women's Hospital</Value></Name></DrugSynonyms><CompanyOriginator id="21048">Brigham &amp; Women's Hospital</CompanyOriginator><CompaniesPrimary><Company id="21048">Brigham &amp; Women's Hospital</Company></CompaniesPrimary><CrossReferences><SourceEntity id="21048" type="Company"><TargetEntity id="4296476182" type="organizationId">Brigham and Women's Hospital Inc</TargetEntity></SourceEntity><SourceEntity id="280" type="ciIndication"><TargetEntity id="804" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="280">Pseudomonas aeruginosa infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="12371">Subunit vaccine</Action><Action id="12378">Prophylactic vaccine</Action><Action id="393">Immunostimulant</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2013-04-11T12:36:58.000Z</LastModificationDate><ChangeDateLast>2012-07-10T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-09T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;The &lt;ulink linkType="Company" linkID="21048"&gt;Brigham and Women's Hospital&lt;/ulink&gt; is investigating conjugate vaccines using Pseudomonas protein PopB as a protein carrier, for the potential prevention of Pseudomonas aeruginosa infection [&lt;ulink linkType="Reference" linkID="1306889"&gt;1306889&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1306877"&gt;1306877&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2012, preclinical data were published. TH17-stimulating protein antigens expressed by a molecular library of DNA encoding Psuedomonas proteins were screened for and PopB was found to be an effective stimulator of TH17 immunity. Mice immunized with purified PopB were protected from lethal pneumonia [&lt;ulink linkType="Reference" linkID="1306889"&gt;1306889&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1306877"&gt;1306877&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21048">Brigham &amp; Women's Hospital</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-21T00:00:00.000Z</StatusDate><Source id="1306889" type="SERIAL"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="144427" title="NHLBI to award Brigham &amp; Women's Hospital funding for the development of vaccines against Pseudomonas aeruginosa infection    "></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>